drugset / Trial / NCT03456817
HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether compared to our standard low dose ATG with CSA, the high dose ATG with low-dose CSA minimizes the chances of relapse and chronic GVHD, without increasing the chances of other transplant complications.
Timeline
- Start
- 2020-07-01
- Primary completion
- 2025-05-31
- Completion
- 2025-05-31
Outcome
Outcome not reported
Stopped (Enrollment): “Slow patient accrual and appearance of a toxicity”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclosporine | Peptide | 2.5 mg/kg | Intravenous |
| Subject | thymoglobulin | Unknown | 2 mg/kg | Intravenous |
| Background | Acetaminophen | Small molecule | — | — |
| Background | Busulfan | Small molecule | — | — |
| Background | Diphenhydramine | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Ibuprofen | Small molecule | — | — |
| Background | Meperidine | Unknown | 25 mg | Intravenous |
| Background | Meperidine | Unknown | 50 mg | Intravenous |
| Background | Methylprednisolone | Other / unclassified | — | — |
| Background | Treatment Arm - high dose ATG | Unknown | 10 mg/m2 | Intravenous |